Tom Cole

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley et al. · The Lancet · 2020 · 2.6K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Regulatory approval and a first‐in‐human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants

Julian K‐C., Jürgen Drossard, D. J. Lewis et al. · Plant Biotechnology Journal · 2015 · 263 citations · Full text

Agriculture, Biotechnology, Plant Biology +16

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

Sonya Abraham, Helene Bæk Juel, Peter Fibiger Bang et al. · The Lancet Infectious Diseases · 2019 · 205 citations

Veterinary Medicine, Immunology, Infectious Diseases +16

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

Katrina M. Pollock, Hannah M. Cheeseman, Alexander J. Szubert et al. · EClinicalMedicine · 2022 · 162 citations · Full text

Pharmacy, Biotechnology, Immunology +16

Therapy-Induced Senescence Drives Bone Loss

Zhangting Yao, Bhavna Murali, Qihao Ren et al. · Cancer Research · 2020 · 127 citations · Full text

Medicine, Cancer Biology, Oncology +12